-
Mashup Score: 3The EKG Guy - 3 month(s) ago
Our mission is to educate, empower, and connect medical professionals around the world. Never fear where your learning journey begins. The learner comes first, and we are here for you! #CardioOncology Our latest Collection spotlights key secondary prevention strategies:? Endocrine Therapies? CDK 4/6 Kinase Inhibitors? CAR-T… Show more Hello #GCU? Which of the following valvular abnormalities is represented by the pressure-time graph? I hope everyone is enjoying the curriculum content. Please, please be
Categories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0Pre-Existing Heart Failure Tied to Higher Mortality in Lymphoma - 12 month(s) ago
DLBCL patients with HF 45% less likely to receive standard first-line anthracyclines, study found
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 1
People with breast cancer are at increased risk of cardiovascular disease, myocardial injury, and heart failure (HF) due to underlying risk factors, a proinflammatory milieu, and cancer therapy–related cardiovascular toxic effects (CTR-CVT).1 Of the therapies for breast cancer, human epidermal…
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 7
Older women with overweight who received cardiotoxic treatment for breast cancer saw a 15% relative CVD risk reduction after following an 8-week time-restricted eating plan, according to research published in JACC: CardioOncology.In a single-arm, feasibility study, researchers also found that older breast cancer survivors who followed a time-restricted eating plan reduced caloric intake without
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0HF from cardiotoxic breast cancer therapies may confer better prognosis vs. other causes - 3 year(s) ago
Women who developed HF following cardiotoxic breast cancer treatment had fewer comorbidities and better overall 5-year prognosis compared with women who developed HF for other reasons, researchers reported. “Anthracycline- and trastuzumab-based chemotherapy are cardiotoxic, contributing to an increased risk of HF in early-stage breast cancer survivors,” Husam Abdel-Qadir, MD, PhD,
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
RT @CardiologyUniv: Learn about #Cardiotoxic cancer treatments with Dr. @nandananavekar ! 🔗https://t.co/radBz7FKLL Stay informed, stay ah…